5 papers in the library · 77 citations · publishing 2018-2022
Human Psychopharmacology Clinical and Experimental March 17, 2022 Edward James, Joachim Keppler, Thomas L Robertshaw et al.
Data sharing is not applicable to this article as no new data were created or analysed in this study.
Human Psychopharmacology Clinical and Experimental February 17, 2022 Edward James, Joachim Keppler, Ben Sessa et al. 41 citations
Abstract Objective Reports have indicated possible uses of ayahuasca for the treatment of conditions including depression, addictions, post‐traumatic stress disorder, anxiety and specific psychoneuroendocrine immune system pathologies. The article assesses potential ayahuasca and N,N‐dimethyltryptamine (DMT) integration with contemporary healthcare. The review also seeks to provide a summary of...
Human Psychopharmacology Clinical and Experimental June 23, 2020 Edward James, Thomas L Robertshaw, Mathew Hoskins et al. 29 citations
Abstract Objective Research into psychedelic therapy models has shown promise for the treatment of specific psychiatric conditions. Mystical‐type experiences occasioned by psilocybin have been correlated with therapeutic benefits and long‐term improvements in positive mental outlook and attitudes. This article aims to provide an overview of the topic, highlight strengths and weaknesses in...
Drug Science Policy and Law 2019 Edward James, Thomas L Robertshaw, Michael Pascoe et al. 3 citations
Background: Contemporary research indicates that the legal classifications of cannabis (Schedule 2, Class B), 3,4-methylenedioxymethamphetamine (MDMA) (Schedule 1, Class A) and psilocybin (Schedule 1, Class A) in the United Kingdom are not entirely based on considerations of harm and therapeutic utility. The legal classifications of the substances discussed are typically determined by...
Drug Science Policy and Law 2018 Edward James, Thomas L Robertshaw, Andrew D. Westwell et al. 4 citations
Background Recreational drug use is a major cause of disease, injury, physical and mental impairment and death in developed countries such as the United Kingdom and the United States. Alcohol, tobacco, cannabis, 3,4-methylenedioxymethamphetamine (MDMA) and psilocybe mushrooms are recreational drugs with capacity to cause harm. Cannabis, MDMA and psilocybin have reported therapeutic...